The Buzz Surrounding: Numinus Wellness Inc. (TSX-V: NUMI) | Financial Buzz

The Buzz Surrounding: Numinus Wellness Inc. (TSX-V: NUMI)

About: 

Numinus is a health care company helping to support the universal desire to heal and be well. Through Numinus Bioscience, Numinus has a Health Canada cannabis testing license that allows the company to test and analyze cannabis products from licensed producers. In addition, through a wholly-owned subsidiary Salvation Botanicals, Numinus is a late-stage applicant to receive a Health Canada standard processing license to produce cannabis products. Numinus also has a dealer’s licence which allows the company to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline. 

Our Behind the Buzz Show Featuring Numinus Wellness Inc:

Our Buzz on the Street Show Featuring Numinus Wellness Inc:

Investor Recap:

Numinus Bioscience

Numinus Bioscience (in alignment with licence holder Salvation Botanicals Ltd) indicates that it helps customers create safe, reliable products through analytical services, full-spectrum testing and contract research. The company’s revenue-generating testing and contract research laboratory is staffed by internationally-acclaimed PhDs with backgrounds in peer-reviewed research, pharmaceutical manufacturing and advanced analytical technologies.

Testing & research facility:

    • 7,000 sq. ft. fully built and paid for testing and research facility.
    • Compnay licence allows us to test, possess, buy and sell MDMA, psilocybin,
      psilocin, DMT and mescaline. Licence to be amended to include R&D
      and packaging.
    • Staffed by internationally-acclaimed PhDs with backgrounds in peerreviewed research, pharmaceutical manufacturing and advanced
      analytical technologies.
    • Utilizing proprietary technology and chromatography, spectroscopy and
      mass spectrometry techniques.

Numinus Wellness Centre:

  • Acquired an operational facility aligned with our model that embraces the exploration of evidence – based use of psychedelic therapies (these therapies are not in use today at our Vancouver facility and will only proceed when approved by regulators). 
  • Professional therapists and integrative health professionals guide people in the use supportive therapies and sophisticated technologies. 
  • Numinus aims to guide suitable candidates in the use of psychedelic assisted therapies when approved by regulators. Numinus will conduct these therapies in a safe, controlled therapeutic environment working in partnership with various
    health and research organizations.

First wellness centre, located in Vancouver, includes:
six treatment rooms, event/studio space, 15+ therapeutic team
including doctors of medicine and naturopathy, and registered nurses.

In the Media

Recent Developments

June 12, 2020 - CORRECTION: Numinus receives Health Canada licence amendment to produce and extract psilocybin from mushrooms Français

Numinus Wellness Inc. (TSX-V: NUMI) (“Numinus” or the “Company”) has received Health Canada approval to amend the Company’s existing Licence under the Controlled Drug and Substances Act to allow Numinus researchers to conduct research to standardize the extraction of psilocybin from mushrooms. The amendment means Numinus is the first publicly traded company in Canada to be granted a licence by Health Canada to conduct research of this kind.

With this regulatory approval, Numinus is able to proceed with the production of naturally sourced, sustainable psilocybin for research purposes that will support the emerging field of psychedelic assisted therapy and research, at lower costs to currently produced synthetic psilocybin. The licence also allows Numinus to develop and licence its own exclusive IP for further product development in partnership with leading research organizations — something the research community has been seeking to secure. The work will be eligible for the Government of Canada’s Scientific Research and Experimental Development (SR&ED) tax incentive program and will lay a foundation for grant applications.

“We are proud to be at the forefront of a new therapeutic category by advancing evidence-based science focused on wellness and personal connection at its core,” says Numinus CEO Payton Nyquvest. “Numinus is the only publicly traded company in Canada approved to develop a consistent psilocybin extraction method from naturally-produced mushrooms at a time when alternative therapeutic methods are increasingly being investigated and demand from clinical research is growing.”

Working from the 7,000 square-foot Numinus Bioscience research facility and laboratory, senior research scientists Dr. Kristina Grotzinger and Dr. Bernd Keller will focus on developing a proprietary extraction method from mushrooms to allow for consistent dosing and application of naturally produced psilocybin. Once a proprietary method has been developed, the Company intends to explore supply agreements with leading research organizations to make use of the product in their clinical and therapeutic work.

Researchers at Johns Hopkins University, the Multidisciplinary Association for Psychedelic Studies (MAPS) and other leading researchers have published studies showing the benefits of psychedelic substances  in treating a range of mental health issues. Further, the US Food and Drug Administration has granted breakthrough therapy status for psilocybin for the treatment of depression — illustrating the growing demand for therapeutic access to psilocybin.

“In most cases, the creation of synthetic compounds are less pure than those found in nature, which is the case with psilocybin,” says Dr. Grotzinger. “There is risk of contamination from solvents, gases and other chemicals, which makes them less safe to work with and requires added safety and processing expense. By working directly with the mushroom in its natural state, these risks are reduced, as is the cost to extract the psilocybin.”  Grotzinger added that standardized plant or fungi extracts are accepted by European standards and are a common dosage form in Europe.

For Full Release: https://www.newswire.ca/news-releases/correction-numinus-receives-health-canada-licence-amendment-to-produce-and-extract-psilocybin-from-mushrooms-894335680.html

June 11, 2020 - Numinus receives Health Canada licence amendment to produce and extract psilocybin from mushrooms Français

Numinus Wellness Inc. (TSX-V:NUMI) (“Numinus” or the “Company”) has received Health Canada approval to amend the Company’s existing Licence under the Controlled Drug and Substances Act to allow Numinus researchers to conduct research to standardize the extraction of psilocybin from mushrooms. The amendment means Numinus is the first publicly traded company in Canada to be granted a licence by Health Canada to conduct research of this kind.

With this regulatory approval, Numinus is able to proceed with the production of naturally sourced, sustainable psilocybin for research purposes that will support the emerging field of psychedelic assisted therapy and research, at lower costs to currently produced synthetic psilocybin. The licence also allows Numinus to develop and licence its own exclusive IP for further product development in partnership with leading research organizations — something the research community has been seeking to secure. The work will be eligible for the Government of Canada’s Scientific Research and Experimental Development (SR&ED) tax incentive program and will lay a foundation for grant applications.

“We are proud to be at the forefront of a new therapeutic category by advancing evidence-based science focused on wellness and personal connection at its core,” says Numinus CEO Payton Nyquvest. “Numinus is the only publicly traded company in Canada approved to develop a consistent psilocybin extraction method from naturally-produced mushrooms at a time when alternative therapeutic methods are increasingly being investigated and demand from clinical research is growing.”

Working from the 7,000 square-foot Numinus Bioscience research facility and laboratory, senior research scientists Dr. Kristina Grotzinger and Dr. Bernd Keller will focus on developing a proprietary extraction method from mushrooms to allow for consistent dosing and application of naturally produced psilocybin. Once a proprietary method has been developed, the Company intends to explore supply agreements with leading research organizations to make use of the product in their clinical and therapeutic work.

Researchers at Johns Hopkins University, the Multidisciplinary Association for Psychedelic Substances (MAPS) and other leading researchers have published studies showing the benefits of psilocybin in treating Post-Traumatic Stress Disorder (PTSD) and other mental health issues. Further, the US Food and Drug Administration has granted breakthrough therapy status for psilocybin for the treatment of PTSD — illustrating the growing demand for therapeutic access to psilocybin.

“In most cases, the creation of synthetic compounds are less pure than those found in nature, which is the case with psilocybin,” says Dr. Grotzinger. “There is risk of contamination from solvents, gases and other chemicals, which makes them less safe to work with and requires added safety and processing expense. By working directly with the mushroom in its natural state, these risks are reduced, as is the cost to extract the psilocybin.”  Grotzinger added that standardized plant or fungi extracts are accepted by European standards and are a common dosage form in Europe.

For Full Release: https://www.newswire.ca/news-releases/numinus-receives-health-canada-licence-amendment-to-produce-and-extract-psilocybin-from-mushrooms-885909186.html

June 3, 2020 - Dr. Devon Christie, MD CCFP RTC IFMCP, joins Numinus as Medical Director Français

Dr. Evan Wood, Numinus Chief Medical Officer, today announced the appointment of Dr. Devon Christie, MD CCFP RTC IFMCP, to the position of Medical Director at Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI) — another key step in the Company’s evolution as a leader in the advancement of psychedelic therapies, treatment and research.

“We are embarking on an exciting journey at Numinus,” Dr. Wood says. “We are working with health authorities, regulators and Colleges to advance research and protocol development to explore the application of psychedelic assisted psychotherapies in safe, controlled therapeutic environments. Devon will play a key role in the Company in helping to design and implement our patient-focused model for when we are able to put these therapies in place.”

Dr. Christie, a clinical instructor with the UBC Department of Medicine, is also a family physician with a focused practice in Multidisciplinary Pain Management. She is a Registered Therapeutic Counsellor emphasizing Relational Somatic Therapy for trauma resolution and she is also trained to deliver both MDMA-assisted psychotherapy for PTSD (MAPS USA) and ketamine-assisted psychotherapy, in a research setting. She is a recognized speaker and expert on the potential for incorporating psychedelic assisted therapies in an improved health care model for the future.

“As a medical doctor, I have always been interested in non-traditional approaches to therapy and treatment,” Dr. Christie says. “My unique and diverse clinical background, combined with rich personal experience helps me better understand and synthesize healing across disciplines — something Numinus is on a mission to achieve.”

In her role as Numinus’s Medical Director, she will lead a working group and advisory team for the purpose of protocol development and establishing a standard of excellence and professionalism in the safe and ethical delivery of Numinus’s new therapies; provide input on the organizational structure and lead the hiring of key clinical staff and contractors to establish the clinical team for the safe delivery of Numinus’ therapies (when psychedelic therapies are approved for use by regulators); and, as plans are developed to establish Numinus clinical sites, assist in the planning and establishment of physical infrastructure and clinic procedures required for delivering Numinus’ services.

For Full Release: https://www.newswire.ca/news-releases/dr-devon-christie-md-ccfp-rtc-ifmcp-joins-numinus-as-medical-director-831135217.html

May 26, 2020 - Dr. Gabor Maté, recognised physician and bestselling author, joins Numinus as Member of the Clinical Advisory Council

Numinus Wellness Inc. (“Numinus”; TSX-V: NUMI) is pleased to announce the appointment of Dr. Gabor Maté, MD, CM, as a Member of the Numinus Clinical Advisory Council. Through over 30 years’ work in family practice, palliative care and addiction medicine, Dr. Maté has pioneered therapies and innovative, trauma-based approaches to mental health. His advocacy for mental health research and awareness have earned him international recognition from the healthcare community.

“We at Numinus are extremely honoured and excited to have someone with Gabor’s pedigree and on-the-ground experience,” says Numinus CEO Payton Nyquvest. “Gabor offers exceptional insight on the mental health landscape and its future, which greatly complements our goals and mission at Numinus.”

As a Member of the Clinical Advisory Council, Dr. Maté will be a vital resource in helping Numinus develop treatments and drive policy changes within the healthcare industry. Additionally, Dr. Maté will also use his network to enhance Numinus’s collaboration with other leading researchers and groups working in mental illness, addiction and trauma treatment.

“Gabor is a well-respected clinician with a wealth of knowledge on the links between trauma and mental health, as well as ways to promote healing,” says Dr. Evan Wood, Chief Medical Officer of Numinus. “He has been on the forefront of innovative mental health strategies for many years and I look forward to collaborating with him to advance the Numinus model.”

Dr. Maté is internationally recognised for his expertise in addiction, trauma, childhood development, and the link between stress and illness. Beyond his work as a medical practitioner, he is a sought-after speaker and bestselling author with reprints in over 25 languages. His book on addiction received the Hubert Evans Prize for literary non-fiction. For his groundbreaking medical work and writing, he has been awarded the Order of Canada, Canada’s highest civilian distinction, and the Civic Merit Award from his hometown of Vancouver, B.C.

As part of his effort to broaden public awareness of mental illness and contribute to the local community, Dr. Maté spent over a decade working in Vancouver’s Downtown Eastside caring for patients facing severe addiction and mental health challenges. Dr. Maté continues to push boundaries and identify new pathways for healing and advancement in mental health.

For Full Release: https://www.newswire.ca/news-releases/dr-gabor-mate-recognised-physician-and-bestselling-author-joins-numinus-as-member-of-the-clinical-advisory-council-865102880.html

May 21, 2020 - Dr. Evan Wood, recognized leader in the field of substance use research and treatment, joins Numinus as Chief Medical Officer

Numinus Wellness Inc. (“Numinus”) is pleased to announce the appointment of Dr. Evan Wood, MD, PhD, ABIM, FASAM, FRCPC, ABAM Diplomat as Chief Medical Officer with Numinus, effective immediately. Dr. Wood, who over a 20-year career has gained international recognition as a leading researcher into addiction, most recently as the Executive Director of the British Columbia Centre on Substance Use (BCCSU) — a leading research organization into the treatment of substance use and addiction.

“This is an exciting day for all of us at Numinus,” says Numinus CEO Payton Nyquvest. “Dr. Wood is a recognized leader in the area of addiction research and treatment and he will play a central role in advancing the Numinus mission to help people heal and be well.”

As Chief Medical Officer with Numinus, Dr. Wood will play a lead role in helping to establish the evolving Numinus models of care, including defining and hiring the medical and therapeutic team. He will also lead the design of an interdisciplinary medical education program, serve as the company’s primary representative in all research partnerships and protocol development, work with regulators and health authority leadership to advance psychedelic therapies, and help ensure Numinus centres operate within all medical and regulatory guidelines.  

“I share the Numinus position that the societal costs of mental illness, addiction, trauma and unmet human potential are much too high,” says Dr. Wood. “My work and the work of others in the field indicate the value of continuing to explore the use of psychedelic substances in safe, controlled therapeutic environments to address these issues, and I look forward to positioning Numinus as a leader in this emerging area of treatment.”

Dr. Wood has had a longstanding interest in psychedelic assisted psychotherapy through his involvement with the Multidisciplinary Association for Psychedelic Studies (MAPS) trial of MDMA assisted psychotherapy and through emerging work examining the potential of psilocybin assisted psychotherapy for a range of mental health disorders.

In addition to his ongoing work with research and clinical activities, Dr. Wood is also a professor of medicine at the University of British Columbia, where he helps lead the university’s efforts in the area of addiction prevention and treatment through a Tier 1 Canada Research Chair. Dr. Wood has previously been the Physician Program Director for Addiction Services at Providence Health Care, Medical Director for Community Addiction Services at Vancouver Coastal Health, and the founding Director of North America’s largest clinical and research fellowship training programs for addiction medicine physicians based at UBC.

Throughout his career, Dr. Wood has played an instrumental role in bringing research ideas from the laboratory into routine use in the health care system.  He was the lead author of the first study to show that HIV treatment could prevent the transmission of HIV infection among those who inject drugs which contributed to a revision of international therapeutic guidelines. Dr. Wood was also the founding principal investigator of Insite, North America’s medically supervised safer injecting facility — a life saving intervention now common in most large Canadian cities. His work in the area of addiction treatment has contributed to the development of innovative and widely adopted provincial and national therapeutic guidelines . In addition to leading transformative health system interventions, Dr. Wood has been regularly funded by the US National Institute on Drug Abuse and has co-authored more than 400 scientific papers. Through his ongoing work with UBC and the BCCSU, Dr. Wood is also the Principal Investigator for the BC Node of the Canadian Research Initiative in Substance Misuse (CRISM) a Canadian Institutes of Health Research funded national addiction research network.

Dr. Wood’s Additional Roles & Resources:

Awards:

  • Selected for the Canadian Institutes of Health Research’s Peter Lougheed Award as the nation’s top New Investigator applicant (2003)
  • Recipient of the Ron Ghitter Award in Human Rights (2006)
  • Recipient of a leadership award from the Canadian Medical Association (2007)
  • Physician of the Year award from the British Medical Journal (2010)

For Full Release: https://www.newswire.ca/news-releases/dr-evan-wood-recognized-leader-in-the-field-of-substance-use-research-and-treatment-joins-numinus-as-chief-medical-officer-886689056.html

May 20, 2020 - Numinus Wellness Inc. commences trading on TSX Venture Exchange as NUMI

With momentum building for the use of psychedelic assisted therapies in addressing the growing problems of mental illness, addiction and trauma, Vancouver-based Numinus Wellness Inc. began trading today on the TSX Venture Exchange under the symbol NUMI as one of the first in-market, fully integrated companies in the psychedelic space in North America.

“This is an exciting day for all of us at Numinus,” says CEO Payton Nyquvest. “We are on a mission to help address the universal desire to heal and be well. We are looking for like-minded investors who share our belief that new approaches and new ways of thinking are needed to supplement existing options.”

Numinus has put a value chain in place comprising three pillars that will be key to the company’s growth:

  • Numinus Wellness plans to offer physical locations where psychedelic-assisted therapies can take place once approved by regulators. The company’s near-term goal is to identify a suitable location and build a purpose-built, flagship wellness centre to conduct psychedelics-assisted therapies in a safe, controlled therapeutic environment when approved by regulators and governing bodies — a process we are helping to support. Numinus Wellness provides a full suite of therapeutic services through a wellness centre in Vancouver; however, psychedelic-assisted therapies are not currently provided.
  • Numinus R&D is creating partnerships with leading research groups to advance practice and understanding in the space.
  • Numinus Bioscience is licensed by Health Canada to test, sell, distribute, and eventually conduct research on psychedelic substances. Sustainable cannabis revenue driven by our testing operations provides us a foundation for growth – differentiating us from others in the psychedelics space.

“We are excited about the future of psychedelics and our focus will solely be on its therapeutic use,” says Nyquvest. “Psychedelics will move forward in a therapeutic and research context, where the application of these substances will only happen in safe, controlled treatment environments. Numinus has these pieces in place today.”

The efficacy of psychedelic therapies are gaining attention. Johns Hopkins University recently announced the Center for Psychedelic and Consciousness Research, a first-of-its-kind $17-million research centre designed to study compounds like LSD and psilocybin for a range of mental health problems, including anorexia, addiction and depression. In 2017, the US Food and Drug Association (FDA) granted Breakthrough Therapy Designation to MDMA for the treatment of PTSD, and MDMA is currently in the final research phase required by the FDA before deciding whether to approve MDMA as a legal prescription treatment for PTSD in the US. British Columbia’s BC Centre on Substance Use has attracted leading researchers in the field to advance evidence-based research into the therapeutic benefits of psychedelics.

For Full Release: https://www.newswire.ca/news-releases/numinus-wellness-inc-commences-trading-on-tsx-venture-exchange-as-numi-848780337.html

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR branding, marketing and advertising for third parties for disseminating news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For numinus wellness inc., financial and corporate news dissemination, FinancialBuzz.com has been compensated twenty thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.